Troponin I Provides Insight Into Cardiotoxicity and the Anthracycline-Trastuzumab Interaction (Q60638396)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20679626%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

editorial

0 references

title

Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20679626%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Troponin I Provides Insight Into Cardiotoxicity and the Anthracycline-Trastuzumab Interaction (English)

1 reference

https://api.crossref.org/works/10.1200/JCO.2010.30.6274

15 June 2024

author name string

Michael S. Ewer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20679626

15 June 2024

Steven M. Ewer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20679626

15 June 2024

language of work or name

English

0 references

publication date

2 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20679626%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

9 February 2020

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2010.30.6274?role=tab

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20679626

http://intl.jco.org/cgi/content/abstract/28/25/3901

15 June 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20679626

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2010.30.6274

15 June 2024

1 reference

https://api.crossref.org/works/10.1200/JCO.2010.30.6274

Journal of Clinical Oncology

15 June 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20679626%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20679626%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20679626%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

3901-3904

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20679626%20AND%20SRC:MED&resulttype=core&format=json

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation

9 February 2020

cites work

1

1 reference

https://api.crossref.org/works/10.1200/JCO.2010.30.6274

Risk factors for doxorubicin-induced congestive heart failure

15 June 2024

2

1 reference

https://api.crossref.org/works/10.1200/JCO.2010.30.6274

Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy

15 June 2024

5

1 reference

https://api.crossref.org/works/10.1200/JCO.2010.30.6274

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity

15 June 2024

6

1 reference

https://api.crossref.org/works/10.1200/JCO.2010.30.6274

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

15 June 2024

7

1 reference

https://api.crossref.org/works/10.1200/JCO.2010.30.6274

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

15 June 2024

8

1 reference

https://api.crossref.org/works/10.1200/JCO.2010.30.6274

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

15 June 2024

10

1 reference

https://api.crossref.org/works/10.1200/JCO.2010.30.6274

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

15 June 2024

12

1 reference

https://api.crossref.org/works/10.1200/JCO.2010.30.6274

Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes

15 June 2024

13

1 reference

https://api.crossref.org/works/10.1200/JCO.2010.30.6274

111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.

15 June 2024

14

1 reference

https://api.crossref.org/works/10.1200/JCO.2010.30.6274

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

15 June 2024

15

1 reference

https://api.crossref.org/works/10.1200/JCO.2010.30.6274

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

15 June 2024

16

1 reference

https://api.crossref.org/works/10.1200/JCO.2010.30.6274

15 June 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20679626%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference